All News
ACR/EULAR Classification Criteria for ANCA vasculitis, updated from prior
Similar disclaimer; these are for use AFTER the diagnosis of small or medium vasculitis has been made
Great international effort, kudos to all involved
#ACR21 #ACRambassador https://t.co/a29TVvzVF7
Mike Putman EBRheum ( View Tweet)
@ACRheum This 👇👇👇idea from @nighat
I moderated a panel of women leaders in a virtual world - one of the attendees is a trainee from a 3rd world country and had a hard time finding ways to get help/collaboration for research studies; she wanted to know what she could do #ACR21 https://t.co/4Jn8jYUXME
TheDaoIndex KDAO2011 ( View Tweet)
#ACR21
new 2022 classification criteria by ACR/EULAR for AAV
💥GPA-Sensitivity-92%, Specificity-94%
💥MPA-Sensitivity-91%, Specificity-94%
💥EGPA-Sensitivity-85%, Specificity-99%
💥Score based https://t.co/61SOl4Tovg
EnvisionRheumat ERheumat ( View Tweet)
Reasons for COVID-19 vaccine hesitancy in rheumatology pts in southeast US based on survey study:
🔰Vaccine being “rushed” or “experimental”
🔰Safety of vaccine in the patients’ rheumatologic diagnoses
🔰Side effects
🔰Concern for Allergic reaction
Abst#1589 #ACR21 @RheumNow https://t.co/xm15KxdA56
swethaann23 swethaann23 ( View Tweet)
Upadacitinib PsA w/axial involvement - post-hoc analysis of SELECT-PsA 1 and S-PsA-2
Statistically greater response in axial dz compared to placebo in both dz dx'ed by investigator alone & on investigator + PRO-based criteria
https://t.co/YPc5fx9wAR
#ACR21 Abst1945 @RheumNow
Pedro Castillo _Castillo_Pedro ( View Tweet)
Retrospective chart review of rheumatic irAE patients:
Persistent rheumatic irAE activity 🔼received GC
Inflammatory arthritis pts 🔼risk of persistent rheumatic irAE
Risk factors for mortality➡️tumor progression➕ continued Rx GC at last follow-up
Abst#1516 #ACR21 @RheumNow https://t.co/KusNaVlEXp
swethaann23 swethaann23 ( View Tweet)
Dr. Alexis Ogdie on opioid use in PsA and axSpA, highlighting need for better interventions.
🔹21% of PsA pts (n=828) and 27% of axSpA (n=334) reported prescription opiate use.
🔹⬆️BASDI & HAQ-DI =>⬆️opiate use & costs
https://t.co/Id658ocDVf
#ACR21 Abst1777 @RheumNow
Pedro Castillo _Castillo_Pedro ( View Tweet)
Prof. Ami Shah: Patients with #scleroderma have an ⬆ risk of #cancer vs. general population
📌Data from 3 recent meta-analysis: Scleroderma pts have 1.4 to 1.8 fold increased risk of cancer
@RheumNow #ACR21 https://t.co/4uQN6y3tIn
sheila RHEUMarampa ( View Tweet)
Dr. Ami Shah shares her approach to cancer screening in patients with #scleroderma👇
@RheumNow #ACR21 https://t.co/chmlGe4iyl
sheila RHEUMarampa ( View Tweet)
TIF1-y: most dominant target in #cancer assoc'd #dermatomyositis
🔷Associated with cancer in every racial group tested; no assoc'n w/ juvenile DM
@RheumNow #ACR21 https://t.co/rPg1CQuNka
sheila RHEUMarampa ( View Tweet)
Factors Associated with Poor Vaccine Response in Rituximab: Dr. Yuzaiful Yusof (@Yuz6Yusof) discusses abstract #0437 presented at the #ACR21 annual meeting.
https://t.co/T0PFiZlbTa https://t.co/idj5T7j7ke
Links:
Dr. John Cush RheumNow ( View Tweet)
JAK Inhibitors in Refractory Adult and Childhood-Onset Still’s Disease
Dr. Bella Mehta ( @bella_mehta) shares abstract findings from #ACR21.
https://t.co/4FyXX5JIyZ https://t.co/YAJOwvLbLS
Links:
Dr. John Cush RheumNow ( View Tweet)
Update on Safety, Effectiveness of SARS-CoV-2 vaccines in SLE from Dr. Yuz Yusof ( @Yuz6Yusof)
It's almost a year since the Pfizer-BioNTech SARS-CoV-2 vaccine has been made available by the FDA under EUA. But is the vaccine safe for people with lupus?
https://t.co/i3HeCvS6El https://t.co/Tn0nWKrK4T
Links:
Dr. John Cush RheumNow ( View Tweet)
AxSpA/ PsA pts who completed ePRO Q between 2018-2021 showed 🔽 trend of PRO mostly in pts on biologic Rx
If ASDAS < 1.3 /PSAID-12 < 2➡️ pts were seen less frequently
⭐️🔽 clinic workload and better disease activity stratification
Abst # 1788 #ACR21 @RheumNow #ACRBest https://t.co/ilSrOjHQAk
swethaann23 swethaann23 ( View Tweet)
Abst 1515
Williams & colleagues studied role of CD4+ and CD8+ PD-1+ T cells in patients with early RA
- CD4+ and CD8+ T PD-1+ T cells were dominant cell types in synovial tissue
- 6 months after treatment, gene expression of CD4+ PD-1+ T cells decreased
#ACR21 @RheumNow https://t.co/TWLym8oHuK
Akhil Sood MD AkhilSoodMD ( View Tweet)
⭐️From 2012 – 2017 NIS data significant 🔽 in sepsis, SSTI, and UTI in patients with PsA despite the increased use of biologics over the years
⭐️No statistical difference pneumonia trend in PsA
Abst# 1783 #ACR21 @Rheumnow https://t.co/ToxgRb0acP
swethaann23 swethaann23 ( View Tweet)
We are live!
RheumNow Daily Recap - #ACR21 https://t.co/ILaj7CImXY via @YouTube
Links:
Dr. John Cush RheumNow ( View Tweet)
Rheumatologists and Healthcare Professionals: Join us tonight for RheumNow's #ACR21 Rheumatology Roundup at 7pm Eastern time - broadcast live on our YouTube Channel. Search RheumNow on YouTube.
https://t.co/dXNzeGFEds https://t.co/TJ7BEuLKsa
Links:
Dr. John Cush RheumNow ( View Tweet)
Direct-to-Patient (DA) PsA Screening Survey sent to patients with Ps without PsA led to earlier diagnosis of PsA in 0.4%(n=1149 patients) as compared to 0.3%(n=1150) receiving standard of care (SOC).
Mean times to PsA diagnosis
66d ▶️ DA
77d ▶️SOC
Abst# 1781 #ACR21 @RheumNow https://t.co/qxjPCU0vnI
swethaann23 swethaann23 ( View Tweet)
⭐️Prevalent drug utilization was not related to enthesitis activity
⭐️Prevalent use of cDMARDs 🔼physician GAS compared to TNFi/IL-17i
⭐️No correlation in disease activity scores amongst the use of different prevalent PsA drug Rx
Abst# 1782 #ACR21 @RheumNow @doctorRBC https://t.co/uzmTP1hZ2P
swethaann23 swethaann23 ( View Tweet)